Financhill
Back

OncoCyte 10K Form

Sell
43

OCX
OncoCyte

Last Price:
2.65
Seasonality Move:
36.67%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

Receive OCX News And Ratings

See the #1 stock for the next 7 days that we like better than OCX

OCX Financial Statistics

Sales & Book Value

Annual Sales: $1.5M
Cash Flow: $-5.64M
Price / Cash Flow: 0
Annual Sales: $0.73
Price / Book: 4.56

Profitability

EPS (TTM): -4.54000
Net Income (TTM): $-43.14M
Gross Margin: $413K
Return on Equity: -211.42%
Return on Assets: -57.93%

OncoCyte Earnings Forecast

Key OncoCyte Financial Ratios

  • The Gross Profit Margin over the past 5 years for OCX is 27.48%.
  • The Selling, General & Administrative Expenses for OCX have been equal to 900.60% of Gross Profit Margin.
  • The Research & Development expenses have been 618.36% of Revenue.
  • The Interest Expense is -0.19% of Operating Income.
  • The Net Earning history of OCX is -1,848.37% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 4 years.

OncoCyte Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: OCX
CUSIP: 68235C
Website: oncocyte.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0.53
Quick Ratio: 0.39

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

OCX Technical Analysis vs Fundamental Analysis

Sell
43
OncoCyte (OCX) is a Sell

Is OncoCyte a Buy or a Sell?

  • OncoCyte stock is rated a Sell
    The current OncoCyte [OCX] share price is $2.75. The Score for OCX is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.